Table 1.

New antifungal formulations or agents approved by US Food and Drug Administration.

Agent	Original Formulation(s)	Year	New Formulation(s)	Year	Indications	Ref.
Azoles
Ketoconazole	Oral tablet*	1981	N/A		Blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis and paracoccidioidomycosis	9,34
Fluconazole	Intravenous injection	1990	Oral suspension	1993	Invasive and mucosal candidiasis, cryptococcal meningitis, and prophylaxis of Candida infections	17,34,123
	Oral tablet
Itraconazole	Oral capsule	1992	Oral solution	1997	Coccidioidomycosis, blastomycosis, histoplasmosis, onychomycosis, mucosal candidiasis, sporotrichosis, paracoccidioidomycosis, chromomycosis, and dermatomycosis	17,34
					Alternative agent: Aspergillosis
Voriconazole	Intravenous injection	2002	N/A		Aspergillosis, invasive and mucosal candidiasis	34,105,123
	Oral tablet				Alternative agent: Fusariosis and Scedosporiosis
	Oral suspension
Posaconazole	Oral suspension	2006	Delayed-release oral tablet	2013	Mucosal candidiasis and prophylaxis of invasive fungal infections	34,105,123
			Intravenous injection	2014
Isavuconazole	Intravenous injection	2015	N/A		Invasive aspergillosis and mucormycosis	11,49
	Oral capsule
Echinocandins
Caspofungin	Intravenous injection	2001	N/A		Invasive and mucosal candidiasis; empiric antifungal therapy in patients with fever and neutropenia,	81,123
					Alternative agent: Aspergillosis
Micafungin	Intravenous injection	2005	N/A		Invasive and mucosal candidiasis, Prophylaxis of Candida infections	81,123,124
Anidulafungin	Intravenous injection	2006	N/A		Invasive and mucosal candidiasis	81,123
Polyenes
Amphotericin B deoxycholate	Intravenous injection	1958	AmB lipid complex	1995	Aspergillosis, cryptococcosis, blastomycosis, invasive candidiasis, Coccidioidomycosis, histoplasmosis, mucormycosis, sporotrichosis, phaeohyphomycosis	71,105,123
			AmB colloidal dispersion	1996
			Liposomal AmB	1997

Note.

^*The oral tablet was initially approved but later withdrawn in 2013; N/A: not available